Glaucoma, Low Tension Medication
- Author: Jacqueline Freudenthal, MD; Chief Editor: Hampton Roy Sr, MD more...
Medication Summary
The goals of pharmacotherapy are to reduce IOP and morbidity and to prevent complications. The goal of therapy with IOP-lowering medications is for a reduction of at least 30%. Nonselective beta-blockers (eg, timolol maleate, levobunolol) are controversial because as visual-field progression is possibly due to secondary aggravated nocturnal arterial hypotension.[15] A systematic review and meta-analysis of 15 randomized clinical trials studying IOP-lowering agents for treatment of normal-tension glaucoma determined that latanoprost, bimatoprost, and timolol were most effective.[16]
Medications for neuroprotection are as follows:
- Calcium channel blockers - Less progression[17]
- Betaxolol - Improved choroidal flow, better visual-field preservation
- Dorzolamide - Increased retinal blood flow velocity in humans
- Brimonidine - Increased retinal ganglion cell survival in rat optic nerve crush injury
Future medications include the following:
- N -methyl-D-aspartate (NMDA) receptor antagonist (Memantine) - Prevents binding of glutamate and resultant calcium influx; blocks rat ganglion cells from glutamate toxicity in rats and blocks toxic level of glutamate in vitreous
- Serotonin S2 receptor antagonist (Naftidrofuryl) - Arteriolar vasodilation, improved blood flow in Raynaud syndrome
- Glutamate antagonists
- Monoamine oxidase inhibitors (Deprenyl) - Neuroprotection in rat crush model
- Neurotrophic factors (Neurotrophins) - Retard apoptosis in cell culture
- Free radical scavengers - Ginkgo biloba extract scavenges free radicals and nitric oxide, improves blood flow (60-120 mg bid)
- Cannabinoids (marijuana) - Reduces IOP with NMDA antagonist and antioxidant activity
Alpha2-adrenergic agonists
Class Summary
Decrease IOP pressure by reducing aqueous humor production.
Brimonidine (Alphagan)
Selective alpha2-receptor that reduces aqueous humor formation and may increase uveoscleral outflow or inhibit inflow.
Carbonic anhydrase inhibitors
Class Summary
By slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport, may inhibit carbonic anhydrase in the ciliary processes of the eye. This effect may decrease aqueous humor secretion, reducing IOP.
Dorzolamide (Trusopt)
Used concomitantly with other topical ophthalmic drug products to lower IOP. If more than 1 ophthalmic drug is being used, administer the drugs at least 10 min apart. Reversibly inhibits carbonic anhydrase, reducing hydrogen ion secretion at renal tubule and increasing renal excretion of sodium, potassium bicarbonate, and water to decrease production of aqueous humor.
Beta-adrenergic blockers
Class Summary
The exact mechanism of ocular antihypertensive action is not established, but it appears to be a reduction of aqueous humor production or inhibition of inflow.
Timolol ophthalmic (Timoptic XE, Timoptic, Blocadren)
May reduce elevated and normal IOP with or without glaucoma by inhibiting inflow.
Levobunolol (AKBeta, Betagan)
Nonselective beta-adrenergic blocking agent that lowers IOP by reducing aqueous humor production and possibly increasing outflow of aqueous humor.
Betaxolol ophthalmic (Betoptic)
Indicated for glaucoma. Selectively blocks beta1-adrenergic receptors with little or no effect on beta2-receptors. Reduces IOP by reducing production of aqueous humor.
Prostaglandin agonists
Class Summary
For reduction of IOP in patients intolerant to other IOP-lowering medications or who do not respond optimally to other IOP-lowering medications.
Travoprost ophthalmic solution (Travatan)
Prostaglandin F2-alpha analog. Selective FP prostanoid receptor agonist believed to reduce IOP by increasing uveoscleral outflow. Used to treat open-angle glaucoma or ocular hypertension.
Unoprostone ophthalmic solution (Rescula)
Prostaglandin F2-alpha analog. Selective FP prostanoid receptor agonist believed to reduce IOP by increasing uveoscleral outflow. Used to treat open-angle glaucoma or ocular hypertension.
Bimatoprost ophthalmic solution (Lumigan)
A prostamide analogue with ocular hypotensive activity. Mimics the IOP-lowering activity of prostamides via the prostamide pathway. Used to reduce IOP in open-angle glaucoma or ocular hypertension.
Latanoprost (Xalatan)
May decrease IOP by increasing outflow of aqueous humor.
Kim KCY, Ahn AMD, Seong SGJ. Does redefining of high intraocular pressure (IOP) according to IOP distribution change prevalence of normal tension glaucoma in Korea? [abstract]. World Glaucoma Congress, 2009. Available at http://www.worldglaucoma.org/WGC/WGC2009/index.php. Accessed July 24, 2009.
Caprioli J, Coleman AL. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology. Jul 2008;115(7):1123-1129.e3. [Medline].
Paul T, Radcliffe N, Shimmio M. Reclassification of normal and high tension glaucoma eyes using corneal compensated IOP [abstract]. World Glaucoma Congress, 2009. Available at http://www.worldglaucoma.org/WGC2009/. Accessed July 28, 2009.
Akopov E, Astakhov Y, Nefedova D. Retinal vessels calibrometry in normal pressure glaucoma evaluation [abstract]. World Glaucoma Congress, 2009. Available at http://www.worldglaucoma.org/WGC/WGC2009/index.php. Accessed July 28, 2009.
Su WW, Cheng ST, Hsu TS, Ho WJ. Abnormal flow-mediated vasodilation in normal-tension glaucoma using a noninvasive determination for peripheral endothelial dysfunction. Invest Ophthalmol Vis Sci. Aug 2006;47(8):3390-4. [Medline].
Delaney Y, Walshe TE, O'Brien C. Vasospasm in glaucoma: clinical and laboratory aspects. Optom Vis Sci. Jul 2006;83(7):406-14. [Medline].
Plange N, Kaup M, Remky A, Arend KO. Prolonged retinal arteriovenous passage time is correlated to ocular perfusion pressure in normal tension glaucoma. Graefes Arch Clin Exp Ophthalmol. Aug 2008;246(8):1147-52. [Medline].
Harris A, Siesky B, Zarfati D, et al. Relationship of cerebral blood flow and central visual function in primary open-angle glaucoma. J Glaucoma. Jan 2007;16(1):159-63. [Medline].
Chauhan BC, Mikelberg FS, Balaszi AG, LeBlanc RP, Lesk MR, Trope GE. Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma. Arch Ophthalmol. Aug 2008;126(8):1030-6. [Medline]. [Full Text].
Asano E, Mochizuki K, Sawada A, Nagasaka E, Kondo Y, Yamamoto T. Decreased nasal-temporal asymmetry of the second-order kernel response of multifocal electroretinograms in eyes with normal-tension glaucoma. Jpn J Ophthalmol. Sep-Oct 2007;51(5):379-89. [Medline].
Michelson G, Waerntges S, Engelhorn T, Doerfler A. Reduced optic radiation volume measured by DTI is correlated by arterial hypertension in normal tension glaucoma [abstract]. World Glaucoma Congress, 2009. Available at http://www.worldglaucoma.org/WGC/WGC2009/index.php. Accessed July 28,2009.
[Guideline] Screening for glaucoma: recommendation statement. US Preventive Services Task Force. National Guideline Clearinghouse. Mar 2005.
[Guideline] Primary open-angle glaucoma. American Academy of Ophthalmology. National Guideline Clearinghouse. 2005.
[Guideline] Comprehensive adult eye and vision examination. American Optometric Association. National Guideline Clearinghouse. 2005.
Orgul S, Zawinka C, Gugleta K, Flammer J. Therapeutic strategies for normal-tension glaucoma. Ophthalmologica. Nov-Dec 2005;219(6):317-23. [Medline].
Cheng JW, Cai JP, Wei RL. Meta-analysis of medical intervention for normal tension glaucoma. Ophthalmology. Jul 2009;116(7):1243-9. [Medline].
Netland PA, Chaturvedi N, Dreyer EB. Calcium channel blockers in the management of low-tension and open-angle glaucoma. Am J Ophthalmol. May 15 1993;115(5):608-13. [Medline].
Takako Nakagami, Yoshio Yamazaki, Fukuko Hayamizu. Prognostic Factors for Progression of Visual Field Damage in Patients with Normal-Tension Glaucoma. Japanese Journal of Ophthalmology. January, 2006;Volume 50, Number 1:38-42.
Abedin S, Simmons RJ, Grant WM. Progressive low-tension glaucoma: treatment to stop glaucomatous cupping and field loss when these progress despite normal intraocular pressure. Ophthalmology. Jan 1982;89(1):1-6. [Medline].
Fraunfelder FT, Roy FH. Current Ocular Therapy. Philadelphia: WB Saunders; 2000:488-9.
Hitchings RA. Low tension glaucoma--its place in modern glaucoma practice. Br J Ophthalmol. Aug 1992;76(8):494-6. [Medline].
Kawabata K, Kimura T, Fujiki K, Murakami A. [Ocular pulse amplitude in patients with open-angle glaucoma, normal-tension glaucoma, and ocular hypertensionby dynamic observing tonometry]. Nippon Ganka Gakkai Zasshi. Dec 2007;111(12):946-52. [Medline].
Stewart WC, Reid KK. Incidence of systemic and ocular disease that may mimic low-tension glaucoma. J Glaucoma. 1992;1:27-31.
Werner E. Progressive normal-tension glaucoma. I. Analysis. J Glaucoma. Dec 1996;5(6):422-6. [Medline].
²Kurtz S, Haber I, Kesler A. Corneal Thickness Measurements in Normal-tension Glaucoma Workups: Is It Worth the Effort?. J Glaucoma. Apr 15 [Epub ahead of print] 2009.
Print
